Fractyl Health, Inc. (GUTS)
Fractyl Health, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Burlington, MA, US. The stock last traded at $0.66, down 11.16% on the session, giving a market capitalisation of $104.5M. On trailing twelve-month figures it carries a trailing P/E of -0.60, a net margin of 0.0%. Its beta of 2.32 implies it has historically moved more than the broad market.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Fractyl Health, Inc. is most often compared with the following Healthcare names: